Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phibro Animal HealthFRA:PB8 76 ROE % is 23.28% as of Jun. 2026, which is 3% above its 10-year median of 22.56. GuruFocus rates FRA:PB8 with a GF Score™ of 76/100 and a GF Value™ of €27.40 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 936 Drug Manufacturers companies, Phibro Animal Health ranks better than 93.91% on this metric.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phibro Animal Health ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's ROE % distribution charts can be found below:
* The bar in red indicates where Phibro Animal Health's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Phibro Animal Health (FRA:PB8) has a ROE % of 23.28% as of Jun. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Phibro Animal Health and its competitors. This is near median its historical median of 22.56. Over the past decade, Phibro Animal Health's ROE % has ranged from 0.90 to 53.48. According to the industry distribution chart, Phibro Animal Health ranks #57 out of 936 companies in the Drug Manufacturers industry, placing it in the top 6.1%.
Is Phibro Animal Health's ROE % too high?
Phibro Animal Health's current ROE % of 23.28% is near median its 10-year median of 22.56. Over the past 10 years, this metric has ranged from a low of 0.90 to a high of 53.48. The Drug Manufacturers industry median ROE % is 6.14. Phibro Animal Health's value of 23.28% is 279.5% above this industry median. Based on the distribution chart, Phibro Animal Health ranks #57 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Phibro Animal Health has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's ROE % compare to XERS and HROW?
According to the Drug Manufacturers industry distribution chart, Phibro Animal Health ranks #57 out of 936 companies for ROE %. This places Phibro Animal Health in the top 6% of its industry — outperforming the majority of peers. The industry median ROE % is 6.14. Phibro Animal Health's value of 23.28% is 279.5% above this benchmark. Historically, Phibro Animal Health's own ROE % has ranged from 0.90 to 53.48 over the past decade. While the company's 10-year median is 22.56 vs. the industry median of 6.14, Phibro Animal Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.14, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phibro Animal Health's current ROE % of 23.28% is 279.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Phibro Animal Health and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phibro Animal Health's current ROE % is 23.28%, which is near median its own 10-year median of 22.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (FRA:PB8) is currently considered Modestly Overvalued. The stock's GF Value™ is €27.40, compared to a current price of €32.60 — trading 19% above its estimated fair value. The current ROE % is 23.28%, which is near median its 10-year median of 22.56 and 279.5% above the Drug Manufacturers industry median of 6.14. Phibro Animal Health's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Phibro Animal Health (FRA:PB8), the current ROE % is 23.28% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phibro Animal Health (FRA:PB8) Overvalued in 2026?
Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued.
The current stock price of €32.60 is trading 19% above its estimated GF Value™ of €27.40.
GuruFocus considers Phibro Animal Health to be Modestly Overvalued.
Key valuation signals for FRA:PB8:
ROE %: 23.28% (near median its 10-year median of 22.56)
GF Value™: €27.40 vs. price of €32.60 (19% above fair value)
Industry Position: 279.5% above the Drug Manufacturers median (#57 of 936)
No single metric tells the full story. See the FRA:PB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
76GF Score
Get the complete analysis for FRA:PB8
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PB8 has been successfully added to your 
